Replimune Group, Inc. (REPL) Stock

Healthcare · Biotechnology · Member of Other US Stocks

Replimune Group, Inc. (REPL) closed at USD 11.39 on 2026-10-14, a change of +9 % over the past year, with a market capitalization of USD 1.11B.

Replimune Group, Inc. recent closing prices

The most recent trading day is not shown. For full charts and indicators use the analysis page.

Replimune Group, Inc. key figures

Previous close

USD 11.39 (2026-10-14)

1-year change

+9 %

Market cap

USD 1.11B

Enterprise value

USD 1.02B

P/E ratio (trailing)

-3.85

P/E ratio (forward)

-6.46

EPS (trailing)

-3.05

EPS (forward)

-1.82

PEG ratio

n/a

Price to book

9.34

Revenue growth

n/a

Earnings growth

n/a

Dividend per share (trailing)

0.00

Short ratio

10.98

Employees

465

Analyst consensus (third-party)

buy

Source: Yahoo Finance via yfinance. Data may be delayed, incomplete or incorrect.

About Replimune Group, Inc.

Replimune Group, Inc., a clinical-stage biotechnology company, focuses on the development and commercialization of oncolytic immunotherapies to treat cancer in the United States and the United Kingdom. The company's proprietary oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF for a range of solid tumors. The company is also developing RP2 that expresses an anti-CTLA-4 antibody-like protein to block the inhibition of the immune response otherwise caused by CTLA-4. The company was founded in 2015 and is headquartered in Woburn, Massachusetts.

Technical indicators and comparison

Show RSI, MACD, EMA, CCI and ADX for Replimune Group, Inc. and compare it with other stocks.